Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chimin Health Management CoSHSE:603222 +0.65%55 EBITDA Margin % is 5.32% as of Jun. 2026, which is 70% below its 10-year median of 17.66. GuruFocus rates SHSE:603222 with a GF Score™ of 55/100 and a GF Value™ of ¥6.25 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Chimin Health Management Co ranks worse than 74.75% on this metric.
Chimin Health Management Co (SHSE:603222) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Chimin Health Management Co EBITDA Margin % Related Terms
Chimin Health Management Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603222 vs ISRG, BDX, RMD: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Chimin Health Management Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chimin Health Management Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Chimin Health Management Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Chimin Health Management Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chimin Health Management Co (SHSE:603222) has a EBITDA Margin % of 5.32% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chimin Health Management Co and its competitors. This is 70% below median its historical median of 17.66. According to the industry distribution chart, Chimin Health Management Co ranks #610 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 74.8%.
Is Chimin Health Management Co's EBITDA Margin % too high?
Chimin Health Management Co's current EBITDA Margin % of 5.32% is 70% below median its 10-year median of 17.66. The Medical Devices & Instruments industry median EBITDA Margin % is 7.88. Chimin Health Management Co's value of 5.32% is 32.5% below this industry median. Based on the distribution chart, Chimin Health Management Co ranks #610 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Chimin Health Management Co has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chimin Health Management Co's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Chimin Health Management Co ranks #610 out of 816 companies for EBITDA Margin %. This places Chimin Health Management Co in the lower half of its industry. The industry median EBITDA Margin % is 7.88. Chimin Health Management Co's value of 5.32% is 32.5% below this benchmark. While the company's 10-year median is 17.66 vs. the industry median of 7.88, Chimin Health Management Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.88, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chimin Health Management Co's current EBITDA Margin % of 5.32% is 32.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Chimin Health Management Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chimin Health Management Co's current EBITDA Margin % is 5.32%, which is 70% below median its own 10-year median of 17.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimin Health Management Co stock overvalued right now?
Based on GuruFocus' analysis, Chimin Health Management Co (SHSE:603222) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥6.25, compared to a current price of ¥7.73 — trading 23.7% above its estimated fair value. The current EBITDA Margin % is 5.32%, which is 70% below median its 10-year median of 17.66 and 32.5% below the Medical Devices & Instruments industry median of 7.88. Chimin Health Management Co's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Chimin Health Management Co (SHSE:603222), the current EBITDA Margin % is 5.32% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chimin Health Management Co (SHSE:603222) Overvalued in 2026?
Based on GuruFocus' analysis, Chimin Health Management Co stock appears to be overvalued.
The current stock price of ¥7.73 is trading 23.7% above its estimated GF Value™ of ¥6.25.
GuruFocus considers Chimin Health Management Co to be Modestly Overvalued.
Key valuation signals for SHSE:603222:
EBITDA Margin %: 5.32% (70% below median its 10-year median of 17.66)
GF Value™: ¥6.25 vs. price of ¥7.73 (23.7% above fair value)
Industry Position: 32.5% below the Medical Devices & Instruments median (#610 of 816)
No single metric tells the full story. See the SHSE:603222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chimin Health Management Co Ltd is engaged in the pharmaceutical industry. It is engaged in the research and development, production and sales of human medicines and medical devices. Its product centers include large volume injection, medical instruments, Nephrology treatment, and medical service. The company has production bases in Taizhou, Shanghai and Spain.
55GF Score
Get the complete analysis for SHSE:603222
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603222 has been successfully added to your 
